search icon
nktr-img

Nektar Therapeutics, Common Stock

NKTR

NAQ

$0.7394

+$0.04

(5.72%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$122.83M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.89M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.63
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.43 L
$1.52 H
$0.7394

About Nektar Therapeutics, Common Stock

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameNKTRSectorS&P500
1-Week Return12.03%0.71%0.79%
1-Month Return-0.18%-5.6%6.04%
3-Month Return-11.98%-11.72%-1.11%
6-Month Return-35.14%-10.81%-2.39%
1-Year Return-46.42%-7.12%11.69%
3-Year Return-78.75%-0.57%42.29%
5-Year Return-96.59%27.64%93.12%
10-Year Return-93.57%75.45%179.21%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue152.91M101.91M92.06M90.12M98.43M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":66.64,"profit":true},{"date":"2022-12-31","value":60.2,"profit":true},{"date":"2023-12-31","value":58.94,"profit":true},{"date":"2024-12-31","value":64.37,"profit":true}]
Cost of Revenue19.48M24.90M21.64M33.77M30.69M[{"date":"2020-12-31","value":57.68,"profit":true},{"date":"2021-12-31","value":73.73,"profit":true},{"date":"2022-12-31","value":64.07,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":90.87,"profit":true}]
Gross Profit133.44M77.01M70.42M56.35M67.74M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":57.71,"profit":true},{"date":"2022-12-31","value":52.77,"profit":true},{"date":"2023-12-31","value":42.23,"profit":true},{"date":"2024-12-31","value":50.77,"profit":true}]
Gross Margin87.26%75.57%76.50%62.53%68.82%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":86.6,"profit":true},{"date":"2022-12-31","value":87.66,"profit":true},{"date":"2023-12-31","value":71.66,"profit":true},{"date":"2024-12-31","value":78.87,"profit":true}]
Operating Expenses513.36M523.11M310.66M190.90M172.94M[{"date":"2020-12-31","value":98.14,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":59.39,"profit":true},{"date":"2023-12-31","value":36.49,"profit":true},{"date":"2024-12-31","value":33.06,"profit":true}]
Operating Income(379.92M)(446.10M)(240.24M)(263.68M)(105.20M)[{"date":"2020-12-31","value":-37992200000,"profit":false},{"date":"2021-12-31","value":-44610300000,"profit":false},{"date":"2022-12-31","value":-24023600000,"profit":false},{"date":"2023-12-31","value":-26368400000,"profit":false},{"date":"2024-12-31","value":-10519800000,"profit":false}]
Total Non-Operating Income/Expense(82.86M)(121.92M)(146.99M)(20.62M)(27.61M)[{"date":"2020-12-31","value":-8286100000,"profit":false},{"date":"2021-12-31","value":-12192100000,"profit":false},{"date":"2022-12-31","value":-14699100000,"profit":false},{"date":"2023-12-31","value":-2062200000,"profit":false},{"date":"2024-12-31","value":-2761400000,"profit":false}]
Pre-Tax Income(443.95M)(523.28M)(364.98M)(276.26M)(119.20M)[{"date":"2020-12-31","value":-44394700000,"profit":false},{"date":"2021-12-31","value":-52328000000,"profit":false},{"date":"2022-12-31","value":-36498300000,"profit":false},{"date":"2023-12-31","value":-27625600000,"profit":false},{"date":"2024-12-31","value":-11920000000,"profit":false}]
Income Taxes493.00K557.00K3.21M(200.00K)(239.00K)[{"date":"2020-12-31","value":15.33,"profit":true},{"date":"2021-12-31","value":17.33,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-6.22,"profit":false},{"date":"2024-12-31","value":-7.43,"profit":false}]
Income After Taxes(444.44M)(523.84M)(368.20M)(276.06M)(118.96M)[{"date":"2020-12-31","value":-44444000000,"profit":false},{"date":"2021-12-31","value":-52383700000,"profit":false},{"date":"2022-12-31","value":-36819800000,"profit":false},{"date":"2023-12-31","value":-27605600000,"profit":false},{"date":"2024-12-31","value":-11896100000,"profit":false}]
Income From Continuous Operations(444.44M)(523.84M)(368.20M)(293.67M)(118.96M)[{"date":"2020-12-31","value":-44444000000,"profit":false},{"date":"2021-12-31","value":-52383700000,"profit":false},{"date":"2022-12-31","value":-36819800000,"profit":false},{"date":"2023-12-31","value":-29366500000,"profit":false},{"date":"2024-12-31","value":-11896100000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(444.44M)(523.84M)(368.20M)(276.06M)(118.96M)[{"date":"2020-12-31","value":-44444000000,"profit":false},{"date":"2021-12-31","value":-52383700000,"profit":false},{"date":"2022-12-31","value":-36819800000,"profit":false},{"date":"2023-12-31","value":-27605600000,"profit":false},{"date":"2024-12-31","value":-11896100000,"profit":false}]
EPS (Diluted)(2.24)(2.85)(1.97)(1.05)(0.77)[{"date":"2020-12-31","value":-224,"profit":false},{"date":"2021-12-31","value":-285,"profit":false},{"date":"2022-12-31","value":-197,"profit":false},{"date":"2023-12-31","value":-105,"profit":false},{"date":"2024-12-31","value":-77,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

NKTR
Cash Ratio 3.08
Current Ratio 3.24

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

NKTR
ROA (LTM) -26.80%
ROE (LTM) -189.46%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

NKTR
Debt Ratio Lower is generally better. Negative is bad. 0.95
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.05

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

NKTR
Trailing PE NM
Forward PE NM
P/S (TTM) 1.49
P/B 9.47
Price/FCF NM
EV/R 0.14
EV/Ebitda NM
PEG 3.22

FAQs

What is Nektar Therapeutics share price today?

Nektar Therapeutics (NKTR) share price today is $0.7394

Can Indians buy Nektar Therapeutics shares?

Yes, Indians can buy shares of Nektar Therapeutics (NKTR) on Vested. To buy Nektar Therapeutics from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NKTR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Nektar Therapeutics be purchased?

Yes, you can purchase fractional shares of Nektar Therapeutics (NKTR) via the Vested app. You can start investing in Nektar Therapeutics (NKTR) with a minimum investment of $1.

How to invest in Nektar Therapeutics shares from India?

You can invest in shares of Nektar Therapeutics (NKTR) via Vested in three simple steps:

  • Click on Sign Up or Invest in NKTR stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Nektar Therapeutics shares
What is Nektar Therapeutics 52-week high and low stock price?

The 52-week high price of Nektar Therapeutics (NKTR) is $1.52. The 52-week low price of Nektar Therapeutics (NKTR) is $0.43.

What is Nektar Therapeutics price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Nektar Therapeutics (NKTR) is 9.47

What is the Market Cap of Nektar Therapeutics?

The market capitalization of Nektar Therapeutics (NKTR) is $122.83M

What is Nektar Therapeutics’s stock symbol?

The stock symbol (or ticker) of Nektar Therapeutics is NKTR

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top